| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
692,010,000 |
| Market
Cap: |
14.03(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$9.08 - $21.32 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 5.8 |
| Insider 6 Months : 5.8 |
| Insider 3/6 Months : 12 |
|
| Guru Rank Number : 341 |
| Guru Rank Value : 6 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Roivant Sciences develops drug candidates in subsidiary companies Co. calls Vants. Co.'s Vants and pipeline include Dermavant Sciences Ltd., which is developing tapinarof for the treatment of psoriasis and atopic dermatitis, with an earlier-stage development pipeline; Immunovant, Inc., which is developing IMVT-1401 for the treatment of Myasthenia Gravis, Warm Autoimmune Hemolytic Anemia and Thyroid Eye Disease; Aruvant Sciences Ltd., which is developing ARU-1801 as a one-time, potentially curative gene therapy for the treatment of sickle cell disease; and Proteovant Sciences, Inc, which is developing heterobifunctional protein degraders for oncology, neurology, and immunology AR Degrader.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
3,315 |
3,315 |
3,315 |
3,315 |
| Total Buy Value |
$49,957 |
$49,957 |
$49,957 |
$49,957 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
7,183,561 |
10,374,064 |
14,939,373 |
20,904,222 |
| Total Sell Value |
$117,260,749 |
$153,424,295 |
$205,024,734 |
$272,895,551 |
| Total People Sold |
2 |
2 |
4 |
7 |
| Total Sell Transactions |
18 |
27 |
46 |
57 |
| End Date |
2025-08-21 |
2025-05-20 |
2024-11-19 |
2023-11-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ramaswamy Vivek |
10% Owner |
– – • |
2025-11-17 |
4 |
S |
$20.51 |
$11,068,222 |
D/D |
(539,650) |
33,653,756 |
|
1% |
|
| Ramaswamy Vivek |
10% Owner |
– – • |
2025-11-14 |
4 |
S |
$20.33 |
$20,892,531 |
D/D |
(1,027,670) |
34,193,406 |
|
-0% |
|
| Ramaswamy Vivek |
10% Owner |
– – • |
2025-11-13 |
4 |
S |
$20.81 |
$5,978,359 |
D/D |
(287,283) |
35,221,076 |
|
1% |
|
| Venker Eric |
President & Immunovant CEO |
• • – |
2025-11-07 |
4 |
AS |
$20.22 |
$4,044,000 |
D/D |
(200,000) |
1,504,959 |
|
-2% |
|
| Venker Eric |
President & Immunovant CEO |
• • – |
2025-11-07 |
4 |
OE |
$3.85 |
$770,000 |
D/D |
200,000 |
1,704,959 |
|
- |
|
| Oren Ilan |
|
• • – |
2025-10-20 |
4 |
D |
$17.74 |
$4,985 |
D/D |
(281) |
118,388 |
|
- |
|
| Oren Ilan |
|
• • – |
2025-10-20 |
4 |
A |
$0.00 |
$0 |
D/D |
1,507 |
118,669 |
|
- |
|
| Epperly Melissa B, |
|
• • – |
2025-10-20 |
4 |
A |
$0.00 |
$0 |
D/D |
1,056 |
56,904 |
|
- |
|
| Momtazee James C |
|
• • – |
2025-10-20 |
4 |
D |
$17.74 |
$2,803 |
D/D |
(158) |
108,543 |
|
- |
|
| Momtazee James C |
|
• • – |
2025-10-20 |
4 |
A |
$0.00 |
$0 |
D/D |
789 |
108,701 |
|
- |
|
| Venker Eric |
President & Immunovant CEO |
• • – |
2025-10-17 |
4 |
AS |
$17.06 |
$2,020,211 |
D/D |
(118,418) |
1,504,959 |
|
18% |
|
| Venker Eric |
President & Immunovant CEO |
• • – |
2025-10-17 |
4 |
OE |
$15.85 |
$1,876,925 |
D/D |
118,418 |
1,623,377 |
|
- |
|
| Venker Eric |
President & Immunovant CEO |
• • – |
2025-10-16 |
4 |
AS |
$17.05 |
$5,426,708 |
D/D |
(318,282) |
1,504,959 |
|
19% |
|
| Venker Eric |
President & Immunovant CEO |
• • – |
2025-10-16 |
4 |
OE |
$15.85 |
$5,044,770 |
D/D |
318,282 |
1,823,241 |
|
- |
|
| Venker Eric |
President & Immunovant CEO |
• • – |
2025-10-15 |
4 |
AS |
$16.93 |
$7,020,583 |
D/D |
(414,683) |
1,504,959 |
|
19% |
|
| Venker Eric |
President & Immunovant CEO |
• • – |
2025-10-15 |
4 |
OE |
$15.85 |
$6,572,726 |
D/D |
414,683 |
1,919,642 |
|
- |
|
| Venker Eric |
President & Immunovant CEO |
• • – |
2025-10-13 |
4 |
AS |
$16.25 |
$336,814 |
D/D |
(20,727) |
1,504,959 |
|
25% |
|
| Venker Eric |
President & Immunovant CEO |
• • – |
2025-10-13 |
4 |
OE |
$15.85 |
$328,523 |
D/D |
20,727 |
1,525,686 |
|
- |
|
| Venker Eric |
President & Immunovant CEO |
• • – |
2025-10-09 |
4 |
AS |
$16.30 |
$1,710,522 |
D/D |
(104,940) |
1,504,959 |
|
26% |
|
| Venker Eric |
President & Immunovant CEO |
• • – |
2025-10-09 |
4 |
OE |
$15.85 |
$1,663,299 |
D/D |
104,940 |
1,609,899 |
|
- |
|
| Venker Eric |
President & Immunovant CEO |
• • – |
2025-10-08 |
4 |
AS |
$16.20 |
$2,245,352 |
D/D |
(138,602) |
1,504,959 |
|
27% |
|
| Venker Eric |
President & Immunovant CEO |
• • – |
2025-10-08 |
4 |
OE |
$7.45 |
$1,119,164 |
D/D |
138,602 |
1,643,561 |
|
- |
|
| Venker Eric |
President & Immunovant CEO |
• • – |
2025-10-07 |
4 |
AS |
$16.15 |
$5,735,850 |
D/D |
(355,161) |
1,504,959 |
|
26% |
|
| Venker Eric |
President & Immunovant CEO |
• • – |
2025-10-07 |
4 |
OE |
$3.85 |
$2,559,093 |
D/D |
355,161 |
1,860,120 |
|
- |
|
| Venker Eric |
President & Immunovant CEO |
• • – |
2025-10-06 |
4 |
AS |
$16.34 |
$2,800,611 |
D/D |
(171,396) |
1,504,959 |
|
25% |
|
528 Records found
|
|
Page 1 of 22 |
|
|
0.07 (0.34%) 
